These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Barry EM; Wang J; Wu T; Davis T; Levine MM Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130 [TBL] [Abstract][Full Text] [Related]
23. Modulation of immune responses following antigen administration by mucosal route. Medina E; Guzmán CA FEMS Immunol Med Microbiol; 2000 Apr; 27(4):305-11. PubMed ID: 10727886 [TBL] [Abstract][Full Text] [Related]
25. Bacteria as DNA vaccine carriers for genetic immunization. Schoen C; Stritzker J; Goebel W; Pilgrim S Int J Med Microbiol; 2004 Oct; 294(5):319-35. PubMed ID: 15532991 [TBL] [Abstract][Full Text] [Related]
26. A new series of mycobacterial expression vectors for the development of live recombinant vaccines. Baulard A; Kremer L; Supply P; Vidaud D; Bidart JM; Bellet D; Locht C Gene; 1996 Oct; 176(1-2):149-54. PubMed ID: 8918246 [TBL] [Abstract][Full Text] [Related]
27. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464 [TBL] [Abstract][Full Text] [Related]
29. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Yu Q; Huang X; Gong P; Zhang Q; Li J; Zhang G; Yang J; Li H; Wang N; Zhang X Vaccine; 2013 Dec; 31(51):6065-71. PubMed ID: 24176493 [TBL] [Abstract][Full Text] [Related]
30. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG. Dietrich G; Viret JF; Hess J Int J Med Microbiol; 2003 Feb; 292(7-8):441-51. PubMed ID: 12635927 [TBL] [Abstract][Full Text] [Related]
33. Recombinant Salmonella vectors in vaccine development. Curtiss R; Kelly SM; Tinge SA; Tacket CO; Levine MM; Srinivasan J; Koopman M Dev Biol Stand; 1994; 82():23-33. PubMed ID: 7958478 [TBL] [Abstract][Full Text] [Related]
34. Live-attenuated bacteria as a cancer vaccine vector. Toussaint B; Chauchet X; Wang Y; Polack B; Le Gouëllec A Expert Rev Vaccines; 2013 Oct; 12(10):1139-54. PubMed ID: 24124876 [TBL] [Abstract][Full Text] [Related]
35. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Loeffler DI; Schoen CU; Goebel W; Pilgrim S Infect Immun; 2006 Jul; 74(7):3946-57. PubMed ID: 16790768 [TBL] [Abstract][Full Text] [Related]
36. Horizontal gene transfer of virulence determinants in selected bacterial foodborne pathogens. Kelly BG; Vespermann A; Bolton DJ Food Chem Toxicol; 2009 May; 47(5):969-77. PubMed ID: 18420327 [TBL] [Abstract][Full Text] [Related]
39. Rational design of Salmonella-based vaccination strategies. Spreng S; Dietrich G; Weidinger G Methods; 2006 Feb; 38(2):133-43. PubMed ID: 16414270 [TBL] [Abstract][Full Text] [Related]
40. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine. Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]